CDC

MADD's "Power of Parents Handbook" Helps Parents In the Fight Against Underage Drinking and Impaired Driving

Retrieved on: 
Tuesday, April 9, 2024
Research, Pennsylvania State University, Nationwide Mutual Insurance Company, Legal drinking age, Medicine, Mother, Crash, Observation, Death, Volunteering, Life, Drinking, Nationwide, CDC, Handbook, Safety, NOT, NHTSA

IRVING, Texas, April 8, 2024 /PRNewswire-PRWeb/ -- The Power of Parents Handbook developed by Mothers Against Drunk Driving® (MADD) and Robert Turrisi, Ph.D., Professor of Biobehavioral Health and Prevention Research Center at Penn State, is helping to equip parents, guardians, and caring adults to have lifesaving conversations with the youth in their lives.

Key Points: 
  • "My collaborative effort with MADD on the Power of Parents is easily the most significant highlight of my career.
  • Being able to make a difference in the lives of so many families is such a great privilege and honor.
  • In addition, numerous studies show that kids say their parents are the leading influence on their decisions about drinking.
  • Parents can download free Power of Parents handbooks for parents of middle school and high school students at http://www.madd.org/powerofparents .

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

Retrieved on: 
Monday, March 25, 2024
Disease, Development, Immunotherapy, Partnership, T1D, Patient, NMRC, Research, Mortality, Death, Breakthrough therapy, Infection, CDC, Vaccination, Safety, SAB, Therapy, Vaccine, Immunoglobulin G, Food

The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.

Key Points: 
  • The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr.
  • SAB has utilized its proprietary DiversitAb™ platform to manufacture SAB-176, fully human polyclonal antibodies targeting influenza from Transchromosomic (Tc) Bovine™.
  • SAB-176 is a novel multi-target biologic that has shown sustained neutralization activity across multiple virus strains of Influenza A and B.
  • Influenza is responsible for approximately 226,000 excess hospitalizations and 30,000 to 50,000 deaths each year in the United States alone.

Hopebridge Gears Up for World Autism Month, Spreads Awareness of 1 in 36 Autism Prevalence

Retrieved on: 
Monday, March 25, 2024
Element, Speech, Social, Prevalence, Learning, Communication, Education, Research, Autism spectrum, Social media, Behavior, CDC, Spectrum, ASD, Residential care

Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.

Key Points: 
  • Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.
  • Hopebridge emphasizes to the public that this is a time to recognize and raise awareness about autism spectrum disorder (ASD) acceptance and inclusion.
  • To Hopebridge, the month of April is an opportunity to ignite change for children, families and the autism community as a whole.
  • "World Autism Month is a time to celebrate the diversity and resilience of individuals on the autism spectrum,” said Hopebridge founder, Kim Strunk.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
Saturday, March 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Retrieved on: 
Friday, March 22, 2024
Diphenhydramine, Anaphylaxis, Hook effect, Pre-exposure prophylaxis, Half-life, Risk, Bone marrow, COVID-19, Patient, Metoprolol, Adrenaline, Epitope, DSM-IV codes, SARS-CoV-2, Death, Adolescence, Bank statement, Post-exposure prophylaxis, Clinical trial, CDC, Antibody, Vaccination, Safety, Immunodeficiency, Vaccine, FDA, Food, Medicine

Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.

Key Points: 
  • Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
  • “The PEMGARDA EUA marks a transformational moment for Invivyd and for the many moderately to severely immunocompromised people who are vulnerable to COVID-19 disease in the U.S.
  • It was developed using INVYMAB™, the company’s platform approach which combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering.
  • The severity of the reactions was generally mild (17/27) or moderate (8/27), but two reactions were life-threatening.

Rate of national measles cases highlights importance of vaccination

Retrieved on: 
Thursday, March 21, 2024
Sneeze, Encephalitis, Head, Measles, Infection, Disease, MMR, Education, Vaccine, Mumps, Rubella, Insurance, Cough, Rash, Mouth, CDC, Vaccination, Safety, Immunodeficiency, Brain damage, Parent, DHSS, Measles vaccine

Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023.

Key Points: 
  • Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023.
  • Infants as young as 6 months can receive the first dose if traveling to areas where the measles infection rate is high.
  • Herd immunity, achieved through a measles vaccination rate of 95% or more, is crucial for preventing disease outbreaks in the community and protecting vulnerable populations who cannot receive vaccines.
  • The measles vaccine, given as part of the MMR (measles, mumps and rubella) vaccine, is extremely effective, giving those vaccinated with just one dose 93% protection against measles infection.

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on: 
Thursday, March 21, 2024
Control, EST, Congress, Lyme disease, CEPI, Coalition, Saint-Herblain, Pan American Health Organization, Walter, PAHO, International Vaccine Institute, Chikungunya, Epidemic, Drug, IVI, CDC, Process, VLA, Euronext Paris, Market access, ACIP, The 24th

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points: 
  • The Company will have a display in the exhibit area of the congress at booth #433.
  • There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
  • Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
  • Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Retrieved on: 
Tuesday, March 19, 2024
COVID, Type, COVID-19, Patient, Heart rate, Research, RVV, Death, Doctor of Philosophy, Trial of the century, Cough, CDC, Harvard University, Fever, Safety, Therapy, Disorder, FDA, Economics, Hospital, Pharmaceutical industry

The Company expects to submit the Type C meeting request by next week.

Key Points: 
  • The Company expects to submit the Type C meeting request by next week.
  • The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms1.
  • David Cutler, PhD, a professor of economics at Harvard University, estimates in a recent research disclosure that the total economic cost of long COVID could be as much as $3.7 trillion2.
  • Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID.

Supreme Court Hears Oral Argument in Pivotal NCLA Case Against Gov’t Social Media Censorship

Retrieved on: 
Monday, March 18, 2024
CISA, Speech, Archive, Freedom, Ethics, COVID-19, Infection, Federation, White, Social media, Public policy, Constitution, First, Bioethics, Immunity, Kulldorff, CDC, Supreme court, DRS, Fifth, COVID-19 vaccine, Constitutional right, Safety, FBI, Injury, Paper, Government, Court, NCLA, Human

The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.

Key Points: 
  • The vast, coordinated silencing of First Amendment-protected speech has targeted influential, highly qualified voices including doctors and scientists like Drs.
  • We went to social media to voice our opinions and were silenced by government employees who bullied social media snowflakes into silencing our voices.
  • In the Murthy v. Missouri case, the Supreme Court has the opportunity to restore the First Amendment in this country.
  • That is what the government did here, and if that is allowed then the First Amendment is a dead letter.”

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.